The study on adverse events induced by pegylated interferon alpha plus ribavirin in chronic hepatitis c

• In: Hospital Pharmacy Section - Posters
• At: Beijing (China) (2007)
• Type: Poster
• Poster code: HPS-P-018
• By: KUO, Shu-Hui (National Cheng Kung University Hospital, Tainan, China Taiwan)
• Co-author(s): Chang, Ting-Tsung (National Cheng Kung University Hospital, TAINAN, China Taiwan)
  Lin, Chia-Yin (National Cheng Kung University Hospital, TAINAN, China Taiwan)
  Tsai, Jui-Chen (National Cheng Kung University Hospital, TAINAN, China Taiwan)
  
• Abstract:

  BACKGROUND The current standard therapy for hepatitis C is a combination of Pegylated interferon and Ribavirin. To avoid adverse reactions, dose reduction during the course of treatment is a commonplace. The tedious handling processes also bring inconveniences to the clinical practice. OBJECTIVE The major purpose of this study is to

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login